SORT1 and Parkinson disease: The anatomical data appear to support the notion that pharmacological modulation of sortilin, as NTR3, may influence the dopaminergic, noradrenergic and cholinergic neurotransmissions, which has been proposed as therapeutic options for Parkinson’s disease, schizophrenia and affective disorders (Gully et al., 1993; Kitabgi, 2002; Kinkead and Nemeroff, 2006; Ferraro et al., 2009; McGonigle, 2012).